# SZ Inhal

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sz-inhal

- Industry: Pharmaceuticals
- Headquarters: Suzhou, China
- Website: www.inhalpharma.com/
- Total disclosed funding: $14M
- Latest round: Series A (Jun 3, 2025)
- Investors on record: 3

## About

Founded in 2020 and based in Suzhou, China, SZ Inhal is a pharmaceutical company that focuses on the research and development of inhaled preparations. Jingxu Zhu, the founder of the company, has more than 20 years of experience in inhaled drug delivery research and development. The company has four departments: formulation development, analysis and testing, inhalation device and mechanical equipment development. In October 2023, SZ Inhal raised over CNY 50 million in series A funding led by new investor E-town Sun Fund. In June 2025, SZ Inhal raised approximately CNY 50 million of series A+ funding from new investors Yishang Huicheng Investment and Zhangzhou Zhanxin Venture Capital. 
 The company's main products include dry powder inhalation formulations, reservoir-type, blister-type, capsule-type and disposable inhalation devices. Its products are used in small molecules, peptides, biological macromolecules and other fields. The company’s revenue is generated by providing inhalation preparations, inhalation devices and supporting equipment.

## Funding rounds

- Series A, Jun 3, 2025, $6.9M — Yishang Huicheng Investment, Zhangzhou Zhanxin Venture Capital
- Series A, Oct 16, 2023, $6.8M — E-town Sun Fund

## Investors

- E-town Sun Fund (https://capitalatlas.ai/funds/e-town-sun-fund) — Series A
- Yishang Huicheng Investment (https://capitalatlas.ai/funds/yishang-huicheng-investment) — Series A
- Zhangzhou Zhanxin Venture Capital (https://capitalatlas.ai/funds/zhangzhou-zhanxin-venture-capital) — Series A